Recombinant Zoster Vaccine Effectively Protects Adults With Rheumatoid Arthritis: Study
Researchers have determined in a new study that the recombinant zoster vaccine (RZV) offers good protection from herpes zoster (HZ) and postherpetic neuralgia (PHN) among adults 50 years and older with rheumatoid arthritis (RA). In addition, scientists did not determine an increased risk of RA flare after vaccination. This study was conducted by Emily R. and fellow researchers was published in the Annals of the Rheumatic Diseases journal.
This retrospective cohort study examined RZV's effectiveness and safety through Kaiser Permanente Southern California data to shed light on vaccine protection for this high-risk group. Vaccine effectiveness (VE) was measured in the study through a retrospective matched cohort analysis.
Adults 50 years and older with RA who were administered two doses of RZV (at least four weeks apart) were matched with unvaccinated controls in a 1:3 ratio. Adjusted hazard ratios (HR) and VE against HZ and PHN were estimated through Cox proportional hazards regression. Safety was assessed by self-controlled case series analysis, determining the risk of RA flares within 30 days of vaccination with conditional Poisson regression.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.